Factors associated with quality of life in human epidermal growth factor receptor 2 positive breast cancer survivors_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Peiwen ¹ , ZHANG Hui ² , LI Mingshuang ³ , CHENG Hanchao ¹ , ZHANG Yuou ¹ ,  SUN Jing ¹ ,  LIN Mengbo ² ,  LIU Yuanli ¹

1. School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100710, P.R.China;
2. Department of Oncology Surgery, Fujian Provincial Hospital, Fuzhou 350001, P.R.China;
3. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100710, P.R.China;

Corresponding author：

SUN Jing, Email: sunjing@pumc.edu.cn; LIN Mengbo, Email: fzsllmb@123.com; LIU Yuanli, Email: yliu@pumc.edu.cn

Keywords：

Human epidermal growth factor receptor 2 positive; Breast cancer; Quality of life; Influencing factor; Logistic regression; Exact logistic regression

DOI：

10.7507/1672-2531.202011085

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the quality of life (QOL) and its influencing factors of patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer returning to social life after treatment.Methods Functional assessment of cancer therapy-breast scale (FACT-B Scale) was adopted to investigate the QOL of the HER2 positive breast cancer survivors, who were admitted and treated during January 2015 and October 2019 in Fujian Provincial Hospital. The demographic, social and economic data, as well as the clinical information of the responded survivors were collected. Logistic regression model was adopted to analyze factors associated with the QOL of the responded survivors.Results A total of 117 responded survivors were included. The median of the FACT-B scale was 106.0 (91.0, 121.3) points out of 148 points (71.6%). With the control of the demographic, social and economic status of the responded survivors, as well as the time from diagnosis and treatment to responding to the follow-up, we found that "having other chronic conditions" was the risk factor for the HER2 positive breast cancer survivors to have higher QOL in the social life after treatment (OR=4.17, 95%CI 1.33 to 15.37, P=0.01).Conclusions The overall QOL of the HER2 positive breast cancer survivors in the social life after treatment was low. "Having other chronic conditions" was the risk factor for the HER2 positive breast cancer survivors to have higher QOL in the social life after treatment.

Citation： ZHANG Peiwen, ZHANG Hui, LI Mingshuang, CHENG Hanchao, ZHANG Yuou, SUN Jing, LIN Mengbo, LIU Yuanli. Factors associated with quality of life in human epidermal growth factor receptor 2 positive breast cancer survivors. Chinese Journal of Evidence-Based Medicine, 2021, 21(5): 532-538. doi: 10.7507/1672-2531.202011085 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	International Agency for Research on Cancer. Estimated number of new cases in 2020, China, females, all ages, 2021-02-04. Available at: https://gco.iarc.fr/today/.
3.	Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 632-641.
4.	朱逸慜, 徐兵河. Her2阳性乳腺癌的精准治疗及研究进展. 中国肿瘤外科杂志, 2020, 12(4): 294-300.
5.	Figueroa-Magalhães MC, Jelovac D, Connolly R, et al. Treatment of HER2-positive breast cancer. Breast, 2014, 23(2): 128-136.
6.	李阁, 谷瑞雪, 刘旭, 等. Her2阳性乳腺癌靶向治疗药物的研究进展. 肿瘤学杂志, 2020, 26(1): 1-6.
7.	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版). 中国癌症杂志, 2019, 29(8): 609-679.
8.	Lidgren M, Wilking N, Jönsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res, 2007, 16(6): 1073-1081.
9.	Kwan ML, Ergas IJ, Somkin CP, et al. Quality of life among women recently diagnosed with invasive breast cancer: the pathways study. Breast Cancer Res Treat, 2010, 123(2): 507-524.
10.	Lu W, Cui Y, Zheng Y, et al. Impact of newly diagnosed breast cancer on quality of life among Chinese women. Breast Cancer Res Treat, 2007, 102(2): 201-210.
11.	徐巧巧, 吕萍, 颜波儿. 乳腺癌患者术后生存质量及影响因素分析. 预防医学, 2017, 29(9): 906-908, 913.
12.	闫静. 乳腺癌患者术后生活质量现状及影响因素研究. 中国药物与临床, 2019, 19(16): 2799-2801.
13.	Ohsumi S, Shimozuma K, Morita S, et al. Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery. Jpn J Clin Oncol, 2009, 39(8): 491-496.
14.	Peerawong T, Phenwan T, Supanitwatthana S, et al. Breast conserving therapy and quality of life in thai females: a mixed methods study. Asian Pac J Cancer Prev, 2016, 17(6): 2917-2921.
15.	Nestle-Krämling C, Andree C. Treatment quality in breast cancer: numbers, age, and breast reconstruction. Dtsch Arztebl Int, 2015, 112(35-36): 575-576.
16.	Rugo H, Brammer M, Zhang F, et al. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer, 2010, 10(4): 288-293.
17.	Jeffe DB, Pérez M, Cole EF, et al. The effects of surgery type and chemotherapy on early-stage breast cancer patients' quality of life over 2-year follow-up. Ann Surg Oncol, 2016, 23(3): 735-743.
18.	方琼, 吴怡颖, 沈莉莉, 等. 不同化疗阶段乳腺癌患者生存质量及影响因素研究. 上海护理, 2019, 19(9): 23-28.
19.	郭雪蓉. 乳腺癌患者生存质量现况及其影响因素研究. 太原: 山西医科大学, 2011.
20.	Shen FR, Liu M, Zhang X, et al. Health-related quality of life among breast cancer patients and its influencing factor in a Chinese population. Asian Pac J Cancer Prev, 2012, 13(8): 3747-3750.
21.	Khater AI, Noaman MK, Abdel Hafiz MN, et al. Health-related quality of life among egyptian female breast cancer patients at the National Cancer Institute, Cairo University. Asian Pac J Cancer Prev, 2019, 20(10): 3113-3119.
22.	Al-Naggar RA, Nagi NM, Ali MM, et al. Quality of life among breast cancer patients in Yemen. Asian Pac J Cancer Prev, 2011, 12(9): 2335-2341.
23.	FACIT group. Functional Assessment of Cancer Therapy–Breast (FACT-B), 2020-10-03. Available at: https://www.facit.org/measures/FACT-B.
24.	Nguyen J, Popovic M, Chow E, et al. EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res, 2015, 4(2): 157-166.
25.	Wan C, Zhang D, Yang Z, et al. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat, 2007, 106(3): 413-418.
26.	中华人民共和国人力资源社会保障部. 关于将36种药品纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知(人社部发〔2017〕54号). Available at: http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201707/t20170718_274153.html.
27.	福建省医疗保障管理委员会办公室. 关于转发人力资源社会保障部将36种药品纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知(闽医保办〔2017〕70号). Available at: http://www.fuzhou.gov.cn/zgfzzt/sybzx/ylbzjj/zchb/201710/t20171031_1808788.htm.
28.	彭慧, 张一英, 黄芳, 等. 上海市嘉定区女性乳腺癌患者生存质量及影响因素研究. 上海预防医学, 2016, 28(2): 80-83, 89.
29.	汪敏, 周海滨, 彭绩, 等. 武汉市早期乳腺癌患者生命质量及影响因素分析. 公共卫生与预防医学, 2006, 17(3): 27-30.
30.	Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer, 2011, 11: 364.
31.	王懿, 王奕, 吴龙风. 保乳术与改良根治术对乳腺癌患者围手术期指标生命质量及生存率的影响. 中国药物与临床, 2018, 18(9): 1568-1570.
32.	刘启军, 曾庆, 周燕荣. 精确logistic回归及其SAS应用程序. 中华流行病学杂志, 2003, 24(8): 725-728.
33.	王彤, 韩宏. 精确logistic回归方法及其医学遗传学应用. 中国卫生统计, 2003, 20(3): 147-150.
34.	张宏. 精确logistic回归模型的应用研究. 南京: 东南大学, 1999.
35.	宋秋艳, 余玲, 董瑞鸿. 2型糖尿病对乳腺癌妇女生命质量影响的研究. 中国实用医药, 2016, 11(12): 1-3.
36.	孔令泉, 李姝, 伍娟, 等. 关注乳腺癌伴随疾病全方位管理之. 中华内分泌外科杂志, 2020, 14(2): 89-93.
37.	马飞, 徐兵河, 邵志敏. 乳腺癌随访及伴随疾病全方位管理指南. 中华肿瘤杂志, 2019, 41(1): 29-41.
38.	黎立喜, 马飞. 乳腺癌全方位和全周期的健康管理模式. 中国医学前沿杂志(电子版), 2020, 12(3): 前插1, 1-5.
39.	李波. 关于基层医院乳腺癌诊治现状的思考. 中华乳腺病杂志(电子版), 2011, 5(5): 512-516.
40.	陈元东, 韦卓, 王源, 等. 乳腺癌诊治规范在基层医院实施情况分析. 中国肿瘤, 2002, 11(12): 707-708.
41.	黄建军, 吴位龙, 毛大华. 贵州省基层医院乳腺癌诊治现状调查. 贵阳医学院学报, 2005, 30(1): 82-83.
42.	穆海英. 医院-社区-家庭一体化延续护理在乳腺癌术后患者中的应用. 齐鲁护理杂志, 2017, 23(14): 40-42.
43.	陈戈, 朱吉, 马恰怡, 等. 基于综合医院-社区协作模式的乳腺癌防治流程构建研究. 中国全科医学, 2018, 21(19): 2291-2296.
44.	杨智聪, 翟焕聪, 沈艳丽, 等. 家庭医生式服务模式对社区乳腺癌患者自我感受负担、负性情绪和生存质量的影响. 中国社区医师, 2019, 35(34): 184-185, 187.
45.	朱晓静. 曲妥珠单抗联合TP化疗对HER2阳性乳腺癌患者的影响. 黑龙江医药科学, 2020, 43(2): 133-134.
46.	赵敏, 戴成燕, 丁平, 等. 曲妥珠单抗联合TC化疗对HER-2阳性晚期乳腺癌外周血及预后影响. 现代肿瘤医学, 2020, 28(14): 2431-2435.
47.	董懿, 王钢乐, 曹技磊. 曲妥珠单抗联合新辅助化疗治疗HER2阳性乳腺癌的临床疗效及对患者生存质量的影响. 癌症进展, 2019, 17(19): 2299-2301.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. International Agency for Research on Cancer. Estimated number of new cases in 2020, China, females, all ages, 2021-02-04. Available at: https://gco.iarc.fr/today/.
3. Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 632-641.
4. 朱逸慜, 徐兵河. Her2阳性乳腺癌的精准治疗及研究进展. 中国肿瘤外科杂志, 2020, 12(4): 294-300.
5. Figueroa-Magalhães MC, Jelovac D, Connolly R, et al. Treatment of HER2-positive breast cancer. Breast, 2014, 23(2): 128-136.
6. 李阁, 谷瑞雪, 刘旭, 等. Her2阳性乳腺癌靶向治疗药物的研究进展. 肿瘤学杂志, 2020, 26(1): 1-6.
7. 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版). 中国癌症杂志, 2019, 29(8): 609-679.
8. Lidgren M, Wilking N, Jönsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res, 2007, 16(6): 1073-1081.
9. Kwan ML, Ergas IJ, Somkin CP, et al. Quality of life among women recently diagnosed with invasive breast cancer: the pathways study. Breast Cancer Res Treat, 2010, 123(2): 507-524.
10. Lu W, Cui Y, Zheng Y, et al. Impact of newly diagnosed breast cancer on quality of life among Chinese women. Breast Cancer Res Treat, 2007, 102(2): 201-210.
11. 徐巧巧, 吕萍, 颜波儿. 乳腺癌患者术后生存质量及影响因素分析. 预防医学, 2017, 29(9): 906-908, 913.
12. 闫静. 乳腺癌患者术后生活质量现状及影响因素研究. 中国药物与临床, 2019, 19(16): 2799-2801.
13. Ohsumi S, Shimozuma K, Morita S, et al. Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery. Jpn J Clin Oncol, 2009, 39(8): 491-496.
14. Peerawong T, Phenwan T, Supanitwatthana S, et al. Breast conserving therapy and quality of life in thai females: a mixed methods study. Asian Pac J Cancer Prev, 2016, 17(6): 2917-2921.
15. Nestle-Krämling C, Andree C. Treatment quality in breast cancer: numbers, age, and breast reconstruction. Dtsch Arztebl Int, 2015, 112(35-36): 575-576.
16. Rugo H, Brammer M, Zhang F, et al. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer, 2010, 10(4): 288-293.
17. Jeffe DB, Pérez M, Cole EF, et al. The effects of surgery type and chemotherapy on early-stage breast cancer patients' quality of life over 2-year follow-up. Ann Surg Oncol, 2016, 23(3): 735-743.
18. 方琼, 吴怡颖, 沈莉莉, 等. 不同化疗阶段乳腺癌患者生存质量及影响因素研究. 上海护理, 2019, 19(9): 23-28.
19. 郭雪蓉. 乳腺癌患者生存质量现况及其影响因素研究. 太原: 山西医科大学, 2011.
20. Shen FR, Liu M, Zhang X, et al. Health-related quality of life among breast cancer patients and its influencing factor in a Chinese population. Asian Pac J Cancer Prev, 2012, 13(8): 3747-3750.
21. Khater AI, Noaman MK, Abdel Hafiz MN, et al. Health-related quality of life among egyptian female breast cancer patients at the National Cancer Institute, Cairo University. Asian Pac J Cancer Prev, 2019, 20(10): 3113-3119.
22. Al-Naggar RA, Nagi NM, Ali MM, et al. Quality of life among breast cancer patients in Yemen. Asian Pac J Cancer Prev, 2011, 12(9): 2335-2341.
23. FACIT group. Functional Assessment of Cancer Therapy–Breast (FACT-B), 2020-10-03. Available at: https://www.facit.org/measures/FACT-B.
24. Nguyen J, Popovic M, Chow E, et al. EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res, 2015, 4(2): 157-166.
25. Wan C, Zhang D, Yang Z, et al. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. Breast Cancer Res Treat, 2007, 106(3): 413-418.
26. 中华人民共和国人力资源社会保障部. 关于将36种药品纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知(人社部发〔2017〕54号). Available at: http://www.mohrss.gov.cn/SYrlzyhshbzb/shehuibaozhang/zcwj/yiliao/201707/t20170718_274153.html.
27. 福建省医疗保障管理委员会办公室. 关于转发人力资源社会保障部将36种药品纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知(闽医保办〔2017〕70号). Available at: http://www.fuzhou.gov.cn/zgfzzt/sybzx/ylbzjj/zchb/201710/t20171031_1808788.htm.
28. 彭慧, 张一英, 黄芳, 等. 上海市嘉定区女性乳腺癌患者生存质量及影响因素研究. 上海预防医学, 2016, 28(2): 80-83, 89.
29. 汪敏, 周海滨, 彭绩, 等. 武汉市早期乳腺癌患者生命质量及影响因素分析. 公共卫生与预防医学, 2006, 17(3): 27-30.
30. Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer, 2011, 11: 364.
31. 王懿, 王奕, 吴龙风. 保乳术与改良根治术对乳腺癌患者围手术期指标生命质量及生存率的影响. 中国药物与临床, 2018, 18(9): 1568-1570.
32. 刘启军, 曾庆, 周燕荣. 精确logistic回归及其SAS应用程序. 中华流行病学杂志, 2003, 24(8): 725-728.
33. 王彤, 韩宏. 精确logistic回归方法及其医学遗传学应用. 中国卫生统计, 2003, 20(3): 147-150.
34. 张宏. 精确logistic回归模型的应用研究. 南京: 东南大学, 1999.
35. 宋秋艳, 余玲, 董瑞鸿. 2型糖尿病对乳腺癌妇女生命质量影响的研究. 中国实用医药, 2016, 11(12): 1-3.
36. 孔令泉, 李姝, 伍娟, 等. 关注乳腺癌伴随疾病全方位管理之. 中华内分泌外科杂志, 2020, 14(2): 89-93.
37. 马飞, 徐兵河, 邵志敏. 乳腺癌随访及伴随疾病全方位管理指南. 中华肿瘤杂志, 2019, 41(1): 29-41.
38. 黎立喜, 马飞. 乳腺癌全方位和全周期的健康管理模式. 中国医学前沿杂志(电子版), 2020, 12(3): 前插1, 1-5.
39. 李波. 关于基层医院乳腺癌诊治现状的思考. 中华乳腺病杂志(电子版), 2011, 5(5): 512-516.
40. 陈元东, 韦卓, 王源, 等. 乳腺癌诊治规范在基层医院实施情况分析. 中国肿瘤, 2002, 11(12): 707-708.
41. 黄建军, 吴位龙, 毛大华. 贵州省基层医院乳腺癌诊治现状调查. 贵阳医学院学报, 2005, 30(1): 82-83.
42. 穆海英. 医院-社区-家庭一体化延续护理在乳腺癌术后患者中的应用. 齐鲁护理杂志, 2017, 23(14): 40-42.
43. 陈戈, 朱吉, 马恰怡, 等. 基于综合医院-社区协作模式的乳腺癌防治流程构建研究. 中国全科医学, 2018, 21(19): 2291-2296.
44. 杨智聪, 翟焕聪, 沈艳丽, 等. 家庭医生式服务模式对社区乳腺癌患者自我感受负担、负性情绪和生存质量的影响. 中国社区医师, 2019, 35(34): 184-185, 187.
45. 朱晓静. 曲妥珠单抗联合TP化疗对HER2阳性乳腺癌患者的影响. 黑龙江医药科学, 2020, 43(2): 133-134.
46. 赵敏, 戴成燕, 丁平, 等. 曲妥珠单抗联合TC化疗对HER-2阳性晚期乳腺癌外周血及预后影响. 现代肿瘤医学, 2020, 28(14): 2431-2435.
47. 董懿, 王钢乐, 曹技磊. 曲妥珠单抗联合新辅助化疗治疗HER2阳性乳腺癌的临床疗效及对患者生存质量的影响. 癌症进展, 2019, 17(19): 2299-2301.

Chinese Journal of Evidence-Based Medicine

Factors associated with quality of life in human epidermal growth factor receptor 2 positive breast cancer survivors

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content